Avanos Medical Reports Q1 2025 Financial Results

Avanos Medical, Inc. ( (AVNS) ) has released its Q1 earnings. Here is a breakdown of the information Avanos Medical, Inc. presented to its investors.

Avanos Medical, Inc., a medical technology company based in Alpharetta, Georgia, specializes in providing innovative healthcare solutions, including enteral feeding and pain management products, aimed at improving patient outcomes and reducing opioid use. In its first quarter of 2025, Avanos Medical reported a slight increase in net sales to $167.5 million, marking a 0.8% rise from the previous year. The company also saw a notable improvement in net income, reaching $6.6 million compared to $0.5 million in the same period last year. Adjusted net income and diluted earnings per share also showed positive growth, indicating enhanced profitability. Key financial metrics highlighted in the report include a stable adjusted EBITDA of $21.6 million and a significant cash flow improvement with a $25.7 million inflow from operations. The Specialty Nutrition Systems segment performed particularly well, with an 8.7% volume growth driven by strong demand in enteral feeding and neonate solutions. However, the Pain Management and Recovery segment faced challenges due to unfavorable currency effects and strategic revenue stream decisions. Looking forward, Avanos Medical maintains its revenue guidance for 2025 but has adjusted its earnings per share expectations due to the impact of tariffs. The company plans to mitigate these effects through cost containment and leveraging international agreements, while remaining cautious about potential tariff-related uncertainties.